IND Swift Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: IND Swift Limited Pharmaceutical Export Portfolio Dataset — 13 Products, $36.7M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

IND Swift Limited — Pharmaceutical Exporter Profile (2026) | 13 Products, $36.7M Trade | TransData Nexus

IND Swift Limited

Indian Pharmaceutical Exporter · Antihistamines & Allergy Specialist · $36.7M Total Trade · DGFT Verified

IND Swift Limited is an Indian pharmaceutical exporter with a total trade value of $36.7M across 13 products in 9 therapeutic categories. Based on 1,476 verified export shipments from Indian Customs (DGFT) records, IND Swift Limited is the #1 Indian exporter in 1 product including Sulfasalazine. Top exports include Fexofenadine ($16.9M), Ramipril ($7.6M), Clarithromycin ($2.9M).

IND Swift Limited — Export Portfolio & Destination Treemap

IND Swift Limited pharmaceutical export portfolio — 13 products across 9 therapeutic categories. Source: Indian Customs (DGFT).

Who is IND Swift Limited? — Company Overview & Market Position

Ind-Swift Limited, established in 1986, is a Chandigarh-based pharmaceutical company specializing in the development and export of finished pharmaceutical formulations. The company was founded by three visionaries: the Mehtas, the Munjals, and the Jains, who aimed to create a global enterprise rooted in ethical practices. Ind-Swift Limited is a privately held entity, with a promoter holding of 55.58% and public holding of 44.42% as of 2024. The company is listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) under the ticker symbols BSE:524652 and NSE:INDSWFTLTD, respectively. As of August 13, 2025, the company's stock price was ₹15.76. Ind-Swift Limited employs approximately 1,054 individuals. The company's official website is www.indswiftltd.com.

What Does IND Swift Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Fexofenadine$16.9M 2Ramipril$7.6M

Product Portfolio — Top 13 by Export Value

IND Swift Limited exports 13 pharmaceutical products across 9 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Fexofenadine	Antihistamines & Allergy	$16.9M	587	13.3%	2
2	Ramipril	Cardiovascular	$7.6M	349	7.1%	5
3	Clarithromycin	Antibiotics	$2.9M	124	2.9%	10
4	Loratadine	Antihistamines & Allergy	$2.0M	88	1.2%	11
5	Ezetimibe	Lipid & Metabolism	$1.8M	144	0.4%	14
6	Terbinafine	Antifungals	$1.4M	48	4.2%	6
7	Pioglitazone	Diabetes & Endocrine	$1.2M	55	3.3%	7
8	Bisacodyl	Gastrointestinal	$1.1M	34	8.8%	2
9	Sulfasalazine	Gastrointestinal	$850.0K	17	21.8%	1
10	Isosorbide	Cardiovascular	$554.6K	15	0.9%	10
11	Ornidazole	Advanced Antibiotics	$172.3K	4	1.0%	14
12	Ceftazidime	Advanced Antibiotics	$149.4K	7	1.4%	15
13	Acarbose	Advanced Diabetes Medications	$145.3K	4	2.2%	6

IND Swift Limited exports 13 pharmaceutical products across 9 therapeutic categories with a total export value of $36.7M. The company is the #1 Indian exporter in 1 product: Sulfasalazine. The top category is Antihistamines & Allergy (51.5% of portfolio), followed by Cardiovascular (22.1%), indicating a concentrated portfolio with the top 5 products accounting for 84.9% of total export value.

IND Swift Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Ind-Swift Limited operates multiple state-of-the-art manufacturing facilities across India, adhering to international quality standards. These facilities are designed to produce a wide range of pharmaceutical dosage forms, including tablets, capsules, syrups, and injections. The company's manufacturing plants are strategically located in regions such as Jammu & Kashmir, Himachal Pradesh, and Punjab, enabling efficient distribution and export operations. The facilities are built according to current guidelines of MHRA, EU, WHO, and accreditations with ISO 14000.

3Key Leadership

The leadership team at Ind-Swift Limited is spearheaded by Chairman and Managing Director NR Munjal, who has been instrumental in the company's growth and strategic direction. The Joint Managing Director is Himanshu Jain, contributing significantly to the company's operations and expansion initiatives. Other key executives include Directors Sahil Munjal and Rishav Mehta, who play pivotal roles in overseeing various aspects of the company's business operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does IND Swift Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Ind-Swift Limited has established a strong presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facilities have received approvals from regulatory bodies such as the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and Australia's Therapeutic Goods Administration (TGA), facilitating market access in these regions. Additionally, Ind-Swift Limited has been involved in exporting its products to Europe, Australia, Canada, South Africa, and Russia, indicating a broad international footprint.

2Emerging Markets

Ind-Swift Limited has made strategic inroads into emerging markets across Africa, Latin America, and Southeast Asia. The company's Global Business Unit (GBU) has received regulatory approvals from the Ministry of Health in the UAE, GCC, and ANVISA in Brazil, enabling market access in these regions. Furthermore, the company's products are available in more than 30 countries worldwide, spanning regions such as the EU, Australia, Central & Latin America, Asia, CIS, and Africa.

3Geographic Strategy

IND Swift Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Ind-Swift Limited's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA), allowing the company to export its pharmaceutical formulations to the United States. The company has filed Abbreviated New Drug Applications (ANDAs) for several products, facilitating market entry. Additionally, Ind-Swift Limited has submitted Drug Master Files (DMFs) to the FDA, providing detailed information about the manufacturing processes and quality controls of its products. The company's facilities have undergone FDA inspections, ensuring compliance with Good Manufacturing Practices (GMP) and maintaining a positive inspection history.

2WHO & EU GMP

Ind-Swift Limited's commitment to quality is evidenced by its adherence to international standards. The company's manufacturing facilities are certified by the World Health Organization's Good Manufacturing Practices (WHO GMP), ensuring the production of safe and effective pharmaceutical products. Additionally, the company holds European Union Good Manufacturing Practice (EU GMP) certificates, facilitating market access in EU member countries. These certifications underscore Ind-Swift Limited's dedication to maintaining high-quality manufacturing processes.

CDSCO & Indian Regulatory

IND Swift Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Ind-Swift Limited operates in a competitive pharmaceutical industry, with several key players in overlapping therapeutic categories. While specific market share data for competitors is not available, Ind-Swift Limited's export value of $36.7 million USD and its leadership in the Sulfasalazine market position it as a significant entity in the global pharmaceutical export sector. The company's diversified product portfolio across 13 products in 9 therapeutic categories enables it to cater to a broad spectrum of market needs, enhancing its competitive edge.

2Key Differentiators

Ind-Swift Limited's key differentiators include its diversified product portfolio, with a focus on high-demand therapeutic categories such as Antihistamines & Allergy, Cardiovascular, and Antibiotics. The company's leadership in the Sulfasalazine market underscores its expertise in specific therapeutic areas. Additionally, Ind-Swift Limited's adherence to international quality standards, evidenced by certifications like WHO GMP and EU GMP, distinguishes it in the global market. The company's strategic geographic diversification further mitigates risks and positions it for sustained growth.

3Strategic Position

Buyer Due Diligence Brief — Evaluating IND Swift Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Ind-Swift Limited has demonstrated a consistent track record in pharmaceutical manufacturing, with an export value of $36.7 million USD across 1,476 shipments. The company's adherence to international quality standards, as evidenced by certifications like WHO GMP and EU GMP, indicates a commitment to product quality and safety. The absence of publicly available records of regulatory non-compliance further suggests reliability in its operations. These factors collectively position Ind-Swift Limited as a dependable supplier in the global pharmaceutical market.

2Certifications to Verify

Importers should verify the following certifications when considering Ind-Swift Limited as a supplier:

FDA Facility Registration: Confirm the company's registration status with the U.S. Food and Drug Administration to ensure compliance with U.S. regulations.

WHO GMP Certification: Verify the company's adherence to the World Health Organization's Good Manufacturing Practices, ensuring product quality and safety.

Frequently Asked Questions — IND Swift Limited

How many pharmaceutical products does IND Swift Limited export from India?

IND Swift Limited exports 13 pharmaceutical products across 9 therapeutic categories. The top exports are Fexofenadine ($16.9M), Ramipril ($7.6M), Clarithromycin ($2.9M), Loratadine ($2.0M), Ezetimibe ($1.8M). Total export value is $36.7M.

What is IND Swift Limited's total pharmaceutical export value?

IND Swift Limited's total pharmaceutical export value is $36.7M, based on 1,476 verified shipments recorded in Indian Customs (DGFT) data.

In which products is IND Swift Limited the #1 Indian exporter?

IND Swift Limited is the #1 Indian exporter in 1 products: Sulfasalazine (21.8% market share).

What therapeutic categories does IND Swift Limited cover?

IND Swift Limited exports across 9 therapeutic categories. The largest are Antihistamines & Allergy (51.5%, 2 products), Cardiovascular (22.1%, 2 products), Antibiotics (7.8%, 1 products).

Get Full IND Swift Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.